Chemotherapy in primary osteogenic sarcoma in patients over the age of forty

• Main Authors: Bulent Ozkurt, Kerem Basarir, Bulent Yalcin, Abdullah Merter, Yusuf Yildiz, Yener Saglik
• Format: Article
• Language: English
• Published: AVES Yayincilik 2017-03-01
• Series: Acta Orthopaedica et Traumatologica Turcica
• Online Access: http://www.sciencedirect.com/science/article/pii/S1017995X16304382

Objective: In this study, we sought to review the clinical and histopathological features and the chemotherapy regimens in osteogenic sarcoma in patients over 40 years of age, and we aimed at identifying the possible prognostic factors in this particular group of patients. Methods: We reviewed 287 patients with osteosarcoma treated between the year 1986 and 2010. Patients from this group who met the following criteria were considered eligible for our study; presence of primary OS, had typical histological and radiographic features of OS, no prior history of cancer or any treatment elsewhere and no prior history of preexisting bone abnormalities. Results: The Kaplan–Meier survival curve for the entire group, with a 95% confidence interval, at two and five years showed the survival rates as 76.2% and 72.8% respectively. The surgical margin was a significant factor affecting the survival. Presence of a pathological fracture also had a significant effect on the survival rate. Conclusion: Osteogenic sarcoma remains a challenging disease to treat. Despite the expectation that elderly patients may not tolerate aggressive modern chemotherapy as the younger patients, we believe that patients with primary OS over the age of 40 should be treated aggressively with effective chemotherapy and complete surgical excision whenever possible. Level of evidence: Level IV, therapeutic study Keywords: Chemotherapy, Elderly, Osteogenic sarcoma, Survival rate